Results 111 to 120 of about 91,870 (284)

Optimal management of Cogan’s syndrome: a multidisciplinary approach [PDF]

, 2017
Cogan's syndrome (CS) is a rare disorder characterized by nonsyphilitic interstitial keratitis (IK) and audio-vestibular symptoms. CS affects mainly young Caucasian adults, mostly during their first three decades of age, and may develop into typical and ...
D'Aguanno, Vittorio, de Vincentiis, Marco, Greco, Antonio, Ralli, Massimo   +3 more
core   +1 more source

Precision Imaging for Optimized Crohn's Disease Management: Navigating the Evolution of Objective Healing Goals

iRADIOLOGY, EarlyView.
Multimodal imaging enables the transition to transmural healing as a superior therapeutic target in Crohn's disease, facilitating precise stricture characterization and the prediction of long‐term clinical outcomes. Some icons are sourced from Figdraw and have been authorized (ID: ROSUUdd4c2).
Ziman Xiong, Yufan Wang, Shuxin Luo, Zhen Li, Yaqi Shen   +4 more
wiley   +1 more source

Periodontitis and high phosphate intake alone or in combination adversely affect the kidney

Journal of Periodontology, EarlyView.
Abstract Background Periodontitis and high phosphate (HP) intake can negatively affect the kidney in the presence of renal disease. This study aimed to evaluate the effects of periodontitis or HP intake, either alone or concurrently, on the periodontal tissue and the kidney under normal renal conditions.
Ae Ri Kim, Min Seo Kim, Jiwon Seo, Eun‐Jung Bak, Yun‐Jung Yoo   +4 more
wiley   +1 more source

Infliximab in the treatment of rheumatoid arthritis

Biologics: Targets & Therapy, 2009
A PerdrigerService de Rhumatologie, CHU de Rennes, Hôpital sud, FranceAbstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA).
A Perdriger
doaj  

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

PLoS ONE
BackgroundThe Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV ...
Nimer S Alkhatib, Abdulaali R Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H Al-Ruthia, Omar Rashdan, Samah Al-Shatnawi, Nahla A Azzam, Mahmoud H Mosli, Amal M Badawoud, Majed S Al Yami, Abdulaziz Alhossan, Ibtisam AlHarbi   +12 more
doaj   +1 more source

Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real‐world clinical settings for children with CD. Methods Data were collected from the prospective ImproveCareNow (ICN) registry for pediatric patients (≥ 2 to <18 years old)
Steven J. Steiner, Jeremy Adler, Shehzad A. Saeed, Richard S. Strauss, Kristin M. Howe, Anna Sheahan, Renping Zhang, Kimberly R. Keihn, Katharine Harrow, Kelly K. Olano, David A. Evans, Kim Hung Lo, Nanhua Zhang, Lilianne Kim, Richard B. Colletti, Sheri Volger, for the ImproveCareNow Learning Health Network, Sabina Ali, Rana Ammoury, Keren L. Appel, Travis Ayers, Howard Baron, Julie Bass, Rachel Bensen, Erica J. Brenner, José Cabrera, Mallory Chavannes, J Fernando del Rosario, Jill Dorsey, Dana M. H. Dykes, Dawn R. Ebach, Bhaskar Gurram, Dyer Heintz, Leslie M. Higuchi, Edward J. Hoffenberg, Jeannie S. Huang, Esther Jacobowitz Israel, Traci W. Jester, Ian Kang, Ian Leibowitz, Tiffany Linville, Ross M. Maltz, Craig A. McKinney, Lybil B. Mendoza Alvarez, Phillip Minar, Tina Morhardt, Alisa J Muñiz Crim, Barbara Joanna Niklinska‐Schirtz, Daniel M. O'Connell, Helen Pappa, Brad Pasternak, Trusha Patel, Meryl K. Perlman, Kelly C. Sandberg, Marc E. Schaefer, Robbyn E. Sockolow, David L. Suskind, Gitit Tomer, Jeanne Tung, Amanda A. Wenzel, Denise D. Young   +60 more
wiley   +1 more source

Risk of Crohn's disease in children presenting with perianal abscess and fistula increases with age: A multicenter study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Perianal abscesses (PA) and fistulas‐in‐ano (FIA) are frequently diagnosed in children and may be presenting symptoms of Crohn's disease (CD). The association between age at presentation of PA/FIA and the risk of subsequent CD development is largely unknown.
Mariëlle Roskam, Thomas Dierikx, Sanne Hulsmann, Jesse Lemmen, Vanessa Leijdekkers, Joanna Luttikhold, Frank Garssen, Mich Dunker, Jarmila van der Bilt, Justin de Jong, Ernst van Heurn, Nanne de Boer, Roel Bakx, Tim de Meij   +13 more
wiley   +1 more source

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [PDF]

, 2017
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy,
Argüelles Arias, Federico, Castro Laria, Luisa, Guerra Veloz, María Fernanda, Maldonado Pérez, Belén, Merino Bohórquez, Vicente, Perea Amarillo, Raúl, Romero Gómez, Manuel, Vilches Arenas, Ángel   +7 more
core  

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young, Jennifer E. Murphy, Mallory Chavannes, Jennifer L. Dotson, Jeanne Tung, Erica Chang, Brad Pasternak, Erin Crawford, Nancy McGreal, Jonathan Moses, Sandra C. Kim   +10 more
wiley   +1 more source

Prevalence of disorders of gut–brain‐interaction in pediatric patients with in‐remission inflammatory bowel disease: An Italian multicenter study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Pediatric patients with in‐remission inflammatory bowel disease (IBD) often report persistent gastrointestinal symptoms, suggesting a potential overlap with disorders of gut–brain‐interaction (DGBIs). While DGBIs affect up to 40% of the general population, their prevalence in quiescent IBD children remains limited.
Giovanna Quatrale, Niccolo’ Chirico, Luigi Colecchia, Giuseppe Stella, Francesco Proli, Pietro Pisano, Erminia Romeo, Paola De Angelis, Licia Pensabene, Giovanni Marasco, Giovanni Di Nardo, Giovanni Barbara, Antonio Gasbarrini, Franco Scaldaferri, Valentina Giorgio   +14 more
wiley   +1 more source